ATOS
Atossa Therapeutics, Inc.NASDAQHealthcare$5.37+4.99%ClosedMarket Cap: $46.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.13
P/S
0.00
EV/EBITDA
-0.08
DCF Value
$4.34
FCF Yield
-67.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.6%
ROA
-73.0%
ROIC
-94.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-11.4M | $-10.9M | $-1.27 | — |
| FY 2025 | $0.00 | -Infinity% | $-37.1M | $-34.8M | $-4.04 | — |
| Q3 2025 | $0.00 | -Infinity% | $-9.3M | $-8.7M | $-1.01 | — |
| Q2 2025 | $0.00 | -Infinity% | $-9.0M | $-8.4M | $-0.98 | — |
| Q1 2025 | $0.00 | -Infinity% | $-7.4M | $-6.7M | $-0.78 | — |
| Q4 2024 | $0.00 | -Infinity% | $-7.2M | $-6.3M | $-0.75 | — |
| FY 2024 | $0.00 | -Infinity% | $-27.6M | $-25.5M | $-3.00 | — |
| Q3 2024 | $0.00 | -Infinity% | $-6.4M | $-7.2M | $-0.86 | — |
| Q2 2024 | $0.00 | -Infinity% | $-7.1M | $-6.0M | $-0.72 | — |
| Q1 2024 | $0.00 | -Infinity% | $-7.0M | $-5.9M | $-0.70 | — |
| Q4 2023 | $18.0K | -77.8% | $-9.0M | $-7.8M | $-0.93 | — |
| FY 2023 | $0.00 | -Infinity% | $-31.4M | $-30.1M | $-3.60 | — |